<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Platelets have been implicated in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> and prognosis </plain></SENT>
<SENT sid="1" pm="."><plain>No population-based study has been reported as to whether preoperative platelet count directly predicts metastatic recurrence of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) patients </plain></SENT>
<SENT sid="2" pm="."><plain>DESIGN: Using a well-characterized cohort of 1,513 surgically resected <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients, we assessed the predictive roles of preoperative platelet count in overall survival, overall recurrence, as well as locoregional and distant metastatic recurrences </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Patients with clinically high platelet count (≥400 × 10(9)/L) measured within 1 month before surgery had a significantly unfavorable survival (hazard ratio [HR] = 1.66, 95 % confidence interval [CI] 1.34-2.05, P = 2.6 × 10(-6), P log rank = 1.1 × 10(-11)) and recurrence (HR =���1.90, 1.24-2.93, P = 0.003, P log rank = 0.003) </plain></SENT>
<SENT sid="4" pm="."><plain>The association of platelet count with recurrence was evident only in patients with metastatic (HR = 2.81, 1.67-4.74, P = 1.1 × 10(-4), P log rank = 2.6 × 10(-6)) but not locoregional recurrence (HR = 0.59, 95 % CI 0.21-1.68, P = 0.325, P log rank = 0.152) </plain></SENT>
<SENT sid="5" pm="."><plain>The findings were internally validated through bootstrap resampling (P &lt; 0.01 at 98.6 % of resampling) </plain></SENT>
<SENT sid="6" pm="."><plain>Consistently, platelet count was significantly higher in deceased than living patients (P &lt; 0.0001) and in patients with metastatic recurrence than locoregional (P = 0.004) or nonrecurrent patients (P &lt; 0.0001) </plain></SENT>
<SENT sid="7" pm="."><plain>Time-dependent modeling indicated that the increased risks for <z:hpo ids='HP_0011420'>death</z:hpo> and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> associated with elevated preoperative platelet counts persisted up to 5 years after surgery </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: Our data demonstrated that clinically high level of preoperative platelets was an independent predictor of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> survival and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>As an important component of the routinely tested complete blood count panel, platelet count may be a cost-effective and noninvasive marker for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> prognosis and a potential intervention target to prevent metastatic recurrence </plain></SENT>
</text></document>